Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 311Carcinoma, Non-Small-Cell Lung 282Prostatic Neoplasms 160Colorectal Neoplasms 155Carcinoma, Hepatocellular 144Neoplasms 134Leukemia, Myeloid, Acute 132Lung Neoplasms 115Squamous Cell Carcinoma of Head and Neck 108Triple Negative Breast Neoplasms 102Multiple Myeloma 102Recurrence 99Pancreatic Neoplasms 94Stomach Neoplasms 93Ovarian Neoplasms 87Neoplasm Metastasis 87Lymphoma, Large B-Cell, Diffuse 81Sarcoma 70Precursor Cell Lymphoblastic Leukemia-Lymphoma 68Esophageal Neoplasms 67Uterine Cervical Neoplasms 66Melanoma 65Brain Neoplasms 65Rectal Neoplasms 62Head and Neck Neoplasms 62Glioblastoma 60Carcinoma, Renal Cell 57Lymphoma 55Myelodysplastic Syndromes 54Esophageal Squamous Cell Carcinoma 54

Interventions

tislelizumab 1RC48 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Cervical Cancer Recurrent × Clear all
NCT06455046 2024-06-12

Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer

Fujian Cancer Hospital

Phase 2 Recruiting
37 enrolled
Gynecologic

Cervical Cancer Recurrent

NCT06063018 2023-10-02

RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

Peking Union Medical College Hospital

Phase 2 Recruiting
30 enrolled
Gynecologic

Cervical Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡